Acquired by Merck in June 2023
RXDX - Prometheus Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
RXDX price evolution
RXDX
| (in millions $) | 1 May 2023 | 31 Jan 2023 | 29 Oct 2022 | 29 Jul 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1.03 | $0.94 | $1.86 | |
| Inventory | ||||
| Total current assets | $726.4 | $708.15 | $266.06 | $219.35 |
| Long term investments | ||||
| Property, plant & equipment | $31.04 | $31.65 | $31.59 | $17.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $758.41 | $740.77 | $298.62 | $237.59 |
| Current liabilities | ||||
| Accounts payable | $1.16 | $0.76 | $1.08 | $0.46 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.34 | $22.82 | $23.78 | $16.47 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $60.8 | $64.81 | $66.08 | $45.76 |
| Shareholders' equity | ||||
| Retained earnings | -$371.97 | -$331.09 | -$292.33 | -$255.05 |
| Other shareholder equity | -$0.23 | -$0.43 | -$0.45 | -$0.31 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1.03 | $1.08 | $1.09 | |
| Inventory | ||||
| Total current assets | $708.15 | $265.38 | $57.46 | $37.53 |
| Long term investments | ||||
| Property, plant & equipment | $31.65 | $1.45 | $0.45 | $0.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $740.77 | $267.8 | $59.63 | $50.48 |
| Current liabilities | ||||
| Accounts payable | $0.76 | $1.15 | $0.96 | $1.4 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $22.82 | $16.44 | $15.26 | $31.88 |
| Long term debt | $11.3 | $8.34 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $64.81 | $32.65 | $31.15 | $43.71 |
| Shareholders' equity | ||||
| Retained earnings | -$331.09 | -$189.34 | -$99.15 | -$37.45 |
| Other shareholder equity | -$0.43 | |||
| Total shareholder equity | ||||
| (in millions $) | 1 May 2023 | 31 Jan 2023 | 30 Oct 2022 | 30 Jul 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.1 | $0.65 | $0.97 | $1.27 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $49.81 | $41.98 | $39.35 | $35.24 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $7.83 | $2.57 | $1.11 | $0.32 |
| Net income | ||||
| Net income | -$40.88 | -$38.76 | -$37.27 | -$33.65 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.81 | $3.13 | $1.23 | $1.12 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $152.59 | $90.93 | $30.24 | $17.09 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $4.03 | -$0.75 | -$2.12 | -$0.76 |
| Net income | ||||
| Net income | -$141.75 | -$90.19 | -$37.14 | -$29.72 |
| Income (for common shares) | ||||
| (in millions $) | 1 May 2023 | 31 Jan 2023 | 30 Oct 2022 | 30 Jul 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$192.33 | -$403.78 | -$183.58 | -$117.82 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $52.8 | $562.2 | $86.87 | $14.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$179.08 | $35.17 | -$178.84 | -$161.29 |
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$403.78 | -$1.14 | -$1.06 | $7.93 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $562.2 | $267.69 | $79.89 | $9.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $35.17 | $203.05 | $50.81 | -$2.51 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 47.71M |
| Revenue | $4.00M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$150.56M |
| Revenue Q/Q | -71.80% |
| Revenue Y/Y | -36.47% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.16 |
|---|---|
| ROA | -29.59% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 37.56 |
| Quick ratio | N/A |